...GeoVax is at the forefront of development for a COVID-19 vaccine and its use of recombinant viruses to generate virus-like particles (VLPs) in vivo has demonstrated considerable immune response for other viruses in a number of human clinical trials.
...GeoVax’s unique VLP-generation technology is exciting, and its commitment to the development of a vaccine for COVID-19 is inspiring. We at Sino Biological are honored to be the exclusive provider of COVID-19-related research reagents to assist their vaccine development efforts,” commented Rob Burgess, Ph.D., Chief Business Officer for Sino Biological.
------
Low float and no dilution past 30 days...
Number of shares of Common Stock outstanding as of April 24, 2020: 13,819,101
Number of shares of Common Stock outstanding as of March 23, 2020: 13,791,601
Market Data 
Markets 
AI
